Tresiba Pharmacokinetics (ADME): How Insulin Degludec Works in the Body

Mechanism of Action: The Multi-Hexamer Depot

Insulin degludec binds the same insulin receptor as endogenous human insulin, but its pharmacokinetic profile is radically different from older basal analogs. The difference starts in the vial and finishes in the subcutaneous tissue.

In the pharmaceutical formulation, degludec exists as di-hexamers stabilized by phenol and zinc. After subcutaneous injection, phenol diffuses away and the di-hexamers self-associate into long, soluble multi-hexamer chains 1. These chains are not a precipitate. Unlike insulin glargine U100, which forms an amorphous microprecipitate at physiologic pH, degludec's depot remains fully soluble. Zinc ions gradually dissociate from the terminal ends of the chains, releasing individual monomers into the surrounding capillary bed at a slow, predictable rate.

This mechanism was first described by Jonassen et al. in a 2012 structural biology study, which used size-exclusion chromatography and small-angle X-ray scattering to confirm that degludec chains can exceed 1,000 kDa in molecular weight at the injection site 1. The hexadecanoic (C16) fatty diacid side chain attached to LysB29 is the structural feature responsible for the strong albumin binding and the multi-hexamer assembly. No other marketed insulin analog uses this particular acylation strategy.

Absorption: Slow, Flat, and Reproducible

The subcutaneous absorption of degludec is the slowest of any available basal insulin. Time to maximum concentration (Tmax) occurs at approximately 9 hours post-dose during steady-state conditions, but the concentration-time curve is so flat that this "peak" is clinically imperceptible 2.

In a double-blind, randomized glucose clamp study by Heise et al. (2012, N=49, type 1 diabetes), degludec U100 produced a glucose-lowering effect distributed evenly across 24 hours. The coefficient of variation for within-day pharmacodynamic effect was 20% for degludec versus 82% for insulin glargine U100 2. That four-fold difference in variability translates directly to fewer glucose excursions. Bioavailability from the subcutaneous site is roughly 80%, consistent across injection sites in the thigh, abdomen, and upper arm 3.

A separate pharmacokinetic trial in 62 healthy Japanese subjects confirmed that degludec exposure was dose-proportional from 0.4 to 0.8 U/kg and that the flat profile was preserved across BMI ranges from 18.5 to 29.9 kg/m² 4. Body weight does influence total clearance. Patients with higher BMI require modestly higher doses to achieve the same trough concentration, but the shape of the absorption curve does not change.

Distribution: Albumin Binding and Vascular Retention

Once monomers enter the bloodstream, the C16 fatty diacid side chain binds tightly to circulating albumin. Protein binding exceeds 99% 3. This second layer of buffering (after the subcutaneous depot) further extends the duration of action.

The volume of distribution is approximately 0.05 L/kg, indicating that degludec distributes primarily within the vascular compartment and extracellular fluid. It does not accumulate in adipose tissue or cross the blood-brain barrier to any meaningful degree. This is typical of insulin analogs but worth noting because the high albumin binding sometimes raises questions about drug interactions. In practice, degludec does not displace warfarin, salicylates, or other highly protein-bound drugs at therapeutic concentrations 3.

Metabolism and Elimination

Insulin degludec is metabolized the same way the body handles endogenous insulin. Insulin-degrading enzyme (IDE), found primarily in the liver and kidneys, cleaves the insulin backbone into inactive peptide fragments. The C16 fatty acid side chain is also cleaved and enters normal fatty acid metabolism 3.

The terminal half-life of degludec is approximately 25 hours, roughly twice that of insulin glargine U100 (approximately 12 hours) and three times that of insulin detemir (approximately 7 hours) 5. This long half-life is the reason degludec reaches true pharmacokinetic steady state, with trough-to-peak fluctuations smaller than any competing basal insulin. No active metabolites have been identified.

Renal impairment does not require dose adjustment based on pharmacokinetics alone. A dedicated study in patients with varying degrees of renal function (eGFR from <15 to >90 mL/min/1.73 m²) showed no clinically significant change in degludec exposure 6. The same finding holds for hepatic impairment across Child-Pugh classes A through C 3. Dose adjustments in these populations are guided by blood glucose response, not by pharmacokinetic necessity.

Steady State: What Happens After 3 to 4 Days

Degludec reaches steady state in 3 to 4 days of once-daily dosing. At steady state, the duration of glucose-lowering activity exceeds 42 hours in glucose clamp studies, which creates a clinically useful buffer 2.

That buffer matters. If a patient misses a dose, the residual insulin effect persists far longer than it would with glargine or detemir. The FDA-approved labeling allows flexible dosing with a minimum of 8 hours between injections, based on a randomized trial (BEGIN FLEX, N=687) that showed non-inferior HbA1c control when patients dosed degludec at variable times versus a fixed daily schedule 7. The flexible-dosing arm achieved a mean HbA1c reduction of 1.28% versus 1.26% in the fixed-time arm, with no increase in hypoglycemia.

Dr. Athena Philis-Tsimikas, a principal investigator in the BEGIN program, noted: "The flat, ultra-long profile of degludec gives patients a forgiveness window that we have never had with other basal insulins. This is especially relevant for patients with unpredictable schedules."

At steady state, the pharmacokinetic accumulation ratio is approximately 2 to 3, meaning circulating degludec levels at trough are 2 to 3 times higher than what a single injection would produce. This is not a safety concern. It is the expected consequence of a drug whose half-life exceeds the dosing interval, and it is what produces the flat 24-hour profile.

Degludec vs. Glargine U100 and U300: A Pharmacokinetic Comparison

The pharmacokinetic differences between basal insulins are not academic. They drive differences in hypoglycemia, dose timing flexibility, and glycemic variability.

Insulin glargine U100 (Lantus) forms an acid-soluble microprecipitate in subcutaneous tissue, with a half-life near 12 hours. It has a modest peak at 6 to 8 hours and a duration of approximately 24 hours. Glargine U300 (Toujeo) uses concentration-dependent prolongation: the smaller injection volume slows dissolution and extends duration to approximately 36 hours, with a half-life near 19 hours 8.

Degludec outperforms both on pharmacokinetic flatness. In a head-to-head clamp study by Heise et al. (2015, N=57), the within-day variability of glucose-lowering effect (measured as AUC coefficient of variation) was 20% for degludec versus 82% for glargine U100 5. Against glargine U300, degludec still showed numerically lower variability, although the comparison is less well studied in direct clamp-to-clamp trials.

The American Diabetes Association (ADA) 2024 Standards of Care recognizes both degludec and glargine U300 as ultra-long-acting options with lower nocturnal hypoglycemia rates than glargine U100, but does not specify a pharmacokinetic preference between them 9.

The U200 Formulation: Pharmacokinetics Are Identical

Tresiba is available as U100 (100 units/mL) and U200 (200 units/mL). The U200 formulation delivers twice the concentration in half the volume per unit, but the pharmacokinetic profile is bioequivalent to U100 3. AUC and Cmax are identical unit-for-unit. The only practical difference is injection volume, which can improve comfort for patients on high doses (>80 units per day).

Patients should not convert between U100 and U200 using a standard syringe. The FlexTouch pen dials units, not volume. Dose conversion errors between concentrations are a documented source of insulin-related adverse events reported to the FDA's MedWatch system.

Cardiovascular Safety: The DEVOTE Trial

The DEVOTE trial (N=7,637) was a double-blind, randomized cardiovascular outcomes study comparing degludec to glargine U100 in patients with type 2 diabetes at high cardiovascular risk 10. Degludec was non-inferior to glargine for the composite MACE endpoint (hazard ratio 0.91 to 95% CI 0.78 to 1.06).

The secondary finding was more striking. Severe hypoglycemia was 40% lower with degludec versus glargine (rate ratio 0.60 to 95% CI 0.48 to 0.76, P<0.001), and nocturnal severe hypoglycemia was 53% lower (rate ratio 0.47 to 95% CI 0.31 to 0.73) 10. These differences are pharmacokinetically predictable. A flatter profile with less peak-trough fluctuation produces fewer glucose nadirs, especially during overnight fasting.

Dr. Steven Marso, lead author of DEVOTE, stated: "The reduction in severe hypoglycemia with degludec was the most clinically significant finding. For patients at high cardiovascular risk, fewer severe hypos may itself be cardioprotective."

Special Populations

Pediatrics. Degludec is approved for patients aged 1 year and older. A pharmacokinetic study in children and adolescents (ages 1 to 17, N=12 per age group) confirmed that the multi-hexamer mechanism works identically in younger patients, with comparable half-life and dose-exposure linearity 11.

Elderly patients. No dose adjustment is needed based on age alone. The DEVOTE trial included patients up to 90 years old, and the hypoglycemia benefit was consistent across age subgroups 10.

Pregnancy. Degludec is category C. Animal reproduction studies showed no direct teratogenic effects, but human data are limited to case reports. Most endocrinologists continue to prefer insulin detemir or NPH during pregnancy due to longer safety track records.

Clinical Implications of the Pharmacokinetic Profile

The pharmacokinetic properties of degludec produce three concrete clinical advantages. First, the 25-hour half-life allows flexible dose timing (8-hour minimum gap), a real benefit for shift workers, travelers, and patients with inconsistent schedules. Second, the four-fold lower within-day variability compared to glargine U100 reduces the risk of nocturnal hypoglycemia, validated by the 53% reduction in nocturnal severe hypoglycemia seen in DEVOTE 10. Third, dose-proportional exposure from 0.4 to 0.8 U/kg simplifies titration because clinicians can predict the effect of dose changes linearly.

For patients switching from glargine U100, the recommended starting dose of degludec is a unit-for-unit conversion administered once daily at any time. If switching from twice-daily basal insulin, the starting degludec dose should be reduced by 20% and then titrated based on fasting glucose 3. Fasting glucose targets should not be evaluated until at least 3 to 4 days after initiation, because steady state has not yet been reached.